読み込み中
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
前日終値
$31.00
+$0.92 · +3.06%
日中の時刻はETです。市場データは遅延する場合があります。
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
日中レンジ
現在 $31.00
52週レンジ
現在 $31.00
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
37
割高
センチメント
65
強気
リスク
27
中程度のリスク
モメンタム
61
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
日中レンジ
現在 $31.00
52週レンジ
現在 $31.00
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 461.9万 USD | — | — | — | — |
| 粗利益 | −461.9万 USD | — | — | — | — |
| 研究開発 | 2.7億 USD | 2.33億 USD | 1.74億 USD | 1.22億 USD | 5591.3万 USD |
| 販売・一般管理 | 6358.3万 USD | 4328.1万 USD | 3437.5万 USD | 2621.2万 USD | 1963.8万 USD |
| 営業費用 | 3.29億 USD | 2.76億 USD | 2.08億 USD | 1.48億 USD | 7555.1万 USD |
| 受取利息 | 1468.9万 USD | 1808.8万 USD | 1307.7万 USD | 398.9万 USD | 46.7万 USD |
| 支払利息 | 306.2万 USD | — | — | 398.9万 USD | — |
| 減価償却費と償却費 | 458.3万 USD | 435.1万 USD | 358.8万 USD | 587.8万 USD | 14.7万 USD |
| 営業利益 | −3.33億 USD | −2.76億 USD | −2.08億 USD | −1.48億 USD | −7555.1万 USD |
| 純利益 | −3.29億 USD | −2.56億 USD | −1.92億 USD | −1.4億 USD | −7227.3万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$51.75
上昇余地（66.94%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2020年11月9日 | 1:4 | — | — |
発効済み 2020年11月9日
1:4
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1.81億0.01%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM1.32億0.17%787.4億 USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB1.31億0.07%1853億 USD0.03%$289.48+0.64%
State Street SPDR S&P Biotech ETFXBI1.19億1.20%98.74億 USD0.35%$153.77+3.00%
Vanguard Morningstar Small-Cap Value ETFVBR8301.73万0.12%682億 USD0.05%$234.43+0.22%
Vanguard Extended Market ETFVXF6949.63万0.07%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO4632.92万0.34%139.17億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB3627.31万0.34%108.2億 USD0.44%$206.49+3.00%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Value ETFVBRVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
